Invitrogen Corporation (NASDAQ: IVGN) Nears Breakout
Says Market Timer Frank Kollar
June 12, 2007 (FinancialWire) (By Frank Kollar)
Invitrogen Corporation (NASDAQ: IVGN), a supplier of sera, cell and tissue culture media and reagents used in life sciences research, as well as in processes to grow cells in the laboratory and produce pharmaceuticals and other high valued proteins, rallied Monday and appears to be setting up for a breakout to new highs.
Shares of Invitrogen have been strong for the past year, with only minor corrections. The weakness over the past two weeks appears to be one of them. A close above $135.50 will point to a continued advance to at least $140.83.
The Fibtimer.com (http://www.fibtimer.com) Stock Timer Portfolio takes positions in stocks that meet its trend timing requirements.
Kollar’s research has shown that the financial markets are in tradable trends approximately 80 percent of the time. FibTimer strategies define trends and trade them in both advancing and declining markets. Caring nothing about what newscasters say or what the latest economic indicator predicts, trends are where the profits are, and that is where FibTimer is.
Kollar is editor and chief analyst at FibTimer.com (http://www.fibtimer.com) which offers market timing strategies for S&P and Nasdaq index fund traders, as well as bond, gold, small cap, sector, ETF and stock trading strategies.
Go to previous Press Releases & Trading Notes.
Note: These "Trading Notes" are short term in nature. They may or may not reflect the same position as current subscriber reports which typically have longer time frames.
© Copyright 1996-2007, Kollar Market Analytics, Inc., All Rights Reserved.
FibTimer reports may not be redistributed without permission. These Trading Notes however may be distributed without permission.
Disclaimer: The financial markets are risky. Investing is risky. Past performance
does not guarantee future performance. The foregoing has been prepared solely
for informational purposes and is not a solicitation, or an offer to buy or sell
any security. Opinions are based on historical research and data believed reliable,
but there is no guarantee that future results will be profitable. |
